| Diabetes Mellitus, Non-Insulin-Dependent
Janumet XR vs Lipitor
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Janumet vs Lipitor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLipitor has a higher rate of injection site reactions vs Janumet based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lipitor but not Janumet, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Janumet
Lipitor
At A Glance
Oral
Once daily
DPP-4 inhibitor / biguanide
Oral
Daily
HMG-CoA reductase inhibitor (statin)
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Myocardial Infarction
- Cerebrovascular accident
- Stable angina
- Diabetes Mellitus, Non-Insulin-Dependent
- Congestive heart failure
- Hyperlipidemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
- Hyperlipoproteinemia Type III
- Hypertriglyceridemia
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Take once daily with a meal; recommended starting dose is 100 mg sitagliptin and 1000 mg metformin HCl extended-release once daily; maximum daily dose is 100 mg sitagliptin and 2000 mg metformin HCl; dose of sitagliptin component limited to 50 mg once daily if eGFR falls below 45 mL/min/1.73 m2; do not split, crush, or chew tablets.
Myocardial Infarction, Cerebrovascular accident, Stable angina, Diabetes Mellitus Non-Insulin-Dependent, Congestive heart failure, Hyperlipidemia, Hyperlipoproteinemia Type III, Hypertriglyceridemia 10 or 20 mg once daily starting; range 10-80 mg once daily; patients requiring LDL-C reduction >45% may start at 40 mg once daily; oral.
Familial hypercholesterolemia - heterozygous Adults: 10 or 20 mg once daily, range 10-80 mg once daily; pediatric patients aged >=10 years: 10 mg once daily starting, range 10-20 mg once daily; oral.
Homozygous Familial Hypercholesterolemia Adults: 10 or 20 mg once daily, range 10-80 mg once daily; pediatric patients aged >=10 years: 10-20 mg once daily starting, range 10-80 mg once daily; oral.
Contraindications
- Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- History of a serious hypersensitivity reaction to JANUMET XR, sitagliptin, or metformin, such as anaphylaxis or angioedema
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to atorvastatin or any excipient in Lipitor
Adverse Reactions
Most common (>=5%) Diarrhea, upper respiratory tract infection, headache (from sitagliptin and metformin coadministration studies); nasopharyngitis (sitagliptin monotherapy); hypoglycemia, diarrhea, nausea (extended-release metformin added to glyburide)
Serious Lactic acidosis, pancreatitis, heart failure, acute renal failure, vitamin B12 deficiency, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid
Postmarketing Anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis, Stevens-Johnson syndrome, hepatic enzyme elevations, fatal and non-fatal hemorrhagic and necrotizing pancreatitis, worsening renal function including acute renal failure, tubulointerstitial nephritis, severe and disabling arthralgia, bullous pemphigoid, constipation, vomiting, myalgia, rhabdomyolysis, cholestatic and hepatocellular liver injury
Most common (>=2%) Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy and rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Pancreatitis, fatigue, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, rhabdomyolysis, myositis, dizziness, peripheral neuropathy, cognitive impairment, myasthenia gravis exacerbation, depression, interstitial lung disease, angioneurotic edema, bullous rashes
Pharmacology
JANUMET XR combines sitagliptin, a selective DPP-4 inhibitor that slows inactivation of incretin hormones (GLP-1 and GIP) to increase insulin release and decrease glucagon in a glucose-dependent manner, and metformin, a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity without altering insulin secretion.
Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of cholesterol; it lowers plasma LDL cholesterol and lipoprotein levels by inhibiting hepatic cholesterol synthesis and upregulating LDL receptor expression on hepatic cell surfaces.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Janumet
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (9/12) · Qty limit (11/12)
Lipitor
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (1/12)
UnitedHealthcare
Janumet
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Lipitor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Janumet
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Lipitor
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Janumet.
No savings programs available for Lipitor.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JanumetView full Janumet profile
LipitorView full Lipitor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.